Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Omer Shvili who wrote (974)	7/10/1998 3:22:00 PM
From: Ariella	Respond to of 1491

Dear Omer, I placed a day order to buy stock at 2 7/16 this morning and have only filled 10% of the order. There is strong support level at the 2 1/2 mark. What you said is true. We're probably going to sit in the mid 2s till real news starts to filter in. Just got to wait for it. If there's any way to be part of conference call, I would really like the info. Think I'll contact company and find out. Nice to hear from you. I'm long FLSHF, TCNOF, OSHSF, VOCLF and CHKPF right now -- wanted to buy DDDDF when it dipped recently but got cold feet -- and keep my eyes toward Ha-Aretz for lots of reasons ;-) Shabbat Shalom, Ariella

To: Omer Shvili who wrote (974)	7/11/1998 9:57:00 AM
From: Ariella	Read Replies (2) \| Respond to of 1491

Dear Omer, I know that people at Pharmos, other Israeli medical people and even some SI posters seem to have thought very little about the Washington Post brief on the American doctor/NIMH announcement of very early clinical work in cannabinoids. "We're much more advanced than they are," is the common retort. Well, from a shareholder perspective, how much does matter if no one knows outside the Israeli medical field? On Wall Street, valuations follow the amount of interest generated for a given company and that usually means people must hear about the company to invest/believe in it. In this respect, because of our lack of Street coverage, PARS shareholders are at a disadvantage. Here's more coverage for the NIMH story. Rather than dismiss it, Pharmos should do some outreach to this publication. NewScientist editors are, after all, knowledgeable about the British debate on allowing more research into cannabis derivatives. And they are devoting a lot of space in their publication to the topic. Moreover, subscribers (potential shareholders?) are writing in too. I'll subscribe to this publication just to write a letter to the editor. Hope other people might too. Hope, especially, that Pharmos will call/e-mail these folks and announce their presence. That's not hype. That's just common sense PR. I was able to buy shares below the $ 2 1/2 mark this week, more than a dime cheaper than Haim Aviv did recently. We need a more pro-active approach to PR! newscientist.com Shalom, Ariella